|
|
|
|
AAO: Higher-Dose Injection No Better for Retinal Vein Occlusion (CME)
by Reuben) //do not remove (will be provided by Reuben) //advnstr + _hbxAccount s_currentYear //populate dynamically SiteCatalyst code version: H.20.3.Copyright 1997-2009 Omniture, Inc. More info available at http://www.omniture.com ADDITIONAL FEATURES ***...
|
|
|
International Stem Cell Corporation Begins Its Second Pre-Clinical Phase of Testing Retinal Pigment Epithelium
Let the jobs come to you!International Stem Cell Corporation (OTCBB: ISCO), www.internationalstemcell.com, announced today that ISCO's Research and Therapeutic Development Group, together with a group of scientists from the University of California, Irvine ...
|
|
|
Canon Showcases Imaging & Workflow Management
Canon U.S.A, Inc., including the CX-1 Hybrid Digital Mydriatic/Non-Mydriatic Retinal Camera1, during Vision Expo East, March 19th 21st, at the Jacob K.Javits Convention Center in New York (booth # MS1050). The CX-1 is the Company's first fully hybrid...
|
|
|
Adjusted Peripapillary Retinal Nerve Fiber Layer Thickness Measurements Based on the Optic Nerve Head Scan Angle
Hong S et al.Current intraretinal imaging devices like OCT assume that the ONH is scanned exactly in front of scanning beam; however, this appears to be inaccurate. Adjusted Peripapillary Retinal Nerve Fiber Layer Thickness Measurements Based on the...
|
|
|
International Stem Cell Corporation Begins Its Second Pre-Clinical Phase of Testing Retinal Pigment Epithelium (RPE) Derived from Human Parthenogenetic Stem Cells for Treatment of Retinal Diseases
(BUSINESS WIRE) ----International Stem Cell Corporation (OTCBB: ISCO), www.internationalstemcell.com, announced today that ISCO's Research and Therapeutic Development Group, together with a group of scientists from the University of California, Irvine (UCI), is...
|
|
|
International Stem Cell Corporation Begins Its Second Pre-Clinical Phase of Testing Retinal Pigment Epithelium (RPE) Derived from Human Parthenogenetic Stem Cells for Treatment of Retinal Diseases
Companies mentioned in this article: International Stem Cell Corporation OCEANSIDE, Calif.-- (BUSINESS WIRE) -- International Stem Cell Corporation (OTCBB: ISCO), www.internationalstemcell.com, announced today that ISCO's Research and Therapeutic Development...
|
|
|
International Stem Cell Corporation Begins Its Second Pre-Clinical Phase of Testing Retinal Pigment Epithelium (RPE) Derived from Human Parthenogeneti
OCEANSIDE, Calif.--(BUSINESS WIRE)--International Stem Cell Corporation (OTCBB: ISCO.OB), www.internationalstemcell.com, announced today that ISCO's Research and Therapeutic Development Group, together with a group of scientists from the University of...
|
|
|
International Stem Cell Corporation Begins Its Second Pre-Clinical Phase of Testing Retinal Pigment Epithelium
International Stem Cell Corporation (OTCBB: ISCO), www.internationalstemcell.com, announced today that ISCO's Research and Therapeutic Development Group, together with a group of scientists from the University of California, Irvine (UCI), is starting a second...
|
|
|
International Stem Cell Corporation Begins Its Second Pre-Clinical Phase of Testing Retinal Pigment Epithelium (RPE) Derived fro
Retinal pigment epithelium (RPE) has been derived from parthenogenetic stem cells by ISCO scientists in close collaboration with UCI scientists.The RPE cells will be tested for the presence of specific markers and for functional activity. Retinal...
|
|
|
ISCO commences second phase of testing RPE derived from parthenogenetic stem cells
International Stem Cell Corporation (OTCBB: ISCO), www.internationalstemcell.com, announced today that ISCO's Research and Therapeutic Development Group, together with a group of scientists from the University of California, Irvine (UCI), is starting a second...
|
|
|
International Stem Cell Corporation Begins Its Second Pre-Clinica...
Company: International Stem Cell Corp (ISCO) International Stem Cell Corporation (OTCBB: ISCO), www.internationalstemcell.com, announced today that ISCO's Research and Therapeutic Development Group, together with a group of scientists from the University of...
|
|
|
Canon U.S.A. Showcases Total Imaging and Workflow Management Solutions at Vision Expo East
Companies mentioned in this article: Canon U.S.A, Inc.NEW YORK -- (BUSINESS WIRE) -- Canon U.S.A, Inc., a leader in digital imaging solutions, will demonstrate the benefits of using its total digital imaging and workflow management solutions, including the...
|
|
|
StockProfiler.US: Small Cap Investor News Alerts: International Stem Cell Corporation & GC China Turbine Corp.
Stock Profiler welcomes investors to sign up at www.stockprofiler.us to subscribe to our FREE Investor Tools, Newsletter, and Market Updates.NOTE: All news contained herein has been previously issued by the companies mentioned in this release, and is the...
|
|
|
Retinal vascular abnormalities and dragged maculae in a carrier with a new NDP mutation (c.268delC) that caused severe Norrie disease in the proband
Lin P et al.There are limited data on signs in female carriers, with mild peripheral retinal abnormalities reported in both carrier and noncarrier females of families with NDP gene mutations. Here, authors report a family harboring a single basepair...
|
|
|
Severe retinal hemorrhages in infants with aggressive, fatal Streptococcus pneumoniae meningitis
Lopez JP et al.Retinal hemorrhages in children occasionally accompany bacterial meningitis, usually due to hemophilus or meningococcal organisms. The hemorrhages may be intraretinal, usually in the posterior pole of the eye and few in number, or,...
|
|
|
DIAGNOS Signs an Agreement with ORA Consulting for the U.S. Food and Drug Administration (FDA) Registration Process
(Marketwire via COMTEX News Network) -- DIAGNOS inc.("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in the use of artificial intelligence and advanced knowledge extraction techniques, and Ora, Inc. ("Ora"), a leader in ophthalmic product...
|
|
|
DIAGNOS Signs an Agreement with ORA Consulting for the U.S. Food and Drug Administration (FDA) Registration Process
BROSSARD, QUEBEC -- (Marketwire) -- 03/16/10 -- DIAGNOS inc.("DIAGNOS" or "the Corporation") (TSX VENTURE: ADK), a leader in the use of artificial intelligence and advanced knowledge extraction techniques, and Ora, Inc. ("Ora"), a leader in ophthalmic...
|
|
|
DIAGNOS Signs an Agreement with ORA Consulting for the U.S. Food and Drug Administration (FDA) Registration Pr
- DIAGNOS inc.('DIAGNOS' or 'the Corporation') (TSX VENTURE:ADK), a leader in the use of artificial intelligence and advanced knowledge extraction techniques, and Ora, Inc. ('Ora'), a leader in ophthalmic product development, announced today that they have...
|
|
|
DIAGNOS Signs an Agreement with ORA Consulting for the U.S. Food and Drug Administration (FDA) Registration Process
BROSSARD, QUEBEC -- (Marketwire) -- 03/16/10 -- DIAGNOS inc.("DIAGNOS" or "the Corporation") (TSX VENTURE: ADK), a leader in the use of artificial intelligence and advanced knowledge extraction techniques, and Ora, Inc. ("Ora"), a leader in ophthalmic...
|
|
|
DIAGNOS Signs an Agreement with ORA Consulting for the U.S. Food and Drug Administration (FDA) Registration Pr
- DIAGNOS inc.('DIAGNOS' or 'the Corporation') (TSX VENTURE:ADK - News), a leader in the use of artificial intelligence and advanced knowledge extraction techniques, and Ora, Inc. ('Ora'), a leader in ophthalmic product development, announced today that...
|
|
|
DIAGNOS Signs an Agreement with ORA Consulting for the U.S. Food and Drug Administration (FDA) Registration Process
BROSSARD, QUEBEC -- (Marketwire) -- 03/16/10 -- DIAGNOS inc.("DIAGNOS" or "the Corporation") (TSX VENTURE: ADK), a leader in the use of artificial intelligence and advanced knowledge extraction techniques, and Ora, Inc. ("Ora"), a leader in ophthalmic...
|
|
|
Cancer drug used to save eyesight
Cancer drug Avastin saves the eyesight of two women Two women suffering from a rare genetic condition have had their eyesight saved by the cancer drug Avastin.Professor Andrew Lotery, a consultant ophthalmologist at Southampton General Hospital's eye unit,...
|
|
|
The Location of the Inferior and Superior Temporal Blood Vessels and Interindividual Variability of the Retinal Nerve Fiber Layer Thickness
_ The Location of the Inferior and Superior Temporal Blood Vessels and Interindividual Variability of the Retinal Nerve Fiber Layer Thickness.
|
|
|
Breakthrough as cancer drug saves the eyesight of two patients with rare genetic condition for the first time
A drug more commonly used to treat breast and lung cancer has been used to save the sight of two patients, doctors revealed today.Professor Andrew Lotery from Southampton General Hospital, used the drug Avastin to treat a rare eyesight disease that affects...
|
|
|
Annual Evidence Update on Retinal Vein Occlusions: 15-19 March 2010
An update of the evidence on this topic from NHS Evidence eyes and vision Guidance from The Royal College of Ophthalmologists and NICE formed the benchmark for the AEU and the following topics have been covered: Introduction Epidemiology Diagnosis Management of...
|
